Answers are grounded in this paper and cite their sources.
Pancreatic cancer is a molecularly heterogeneous disease. Epigenetic changes and epigenetic regulatory mechanisms underlie at least some of this heterogeneity and contribute to the evolution of aggressive tumor biology in patients and the tumor's intrinsic resistance to therapy. Here we review our current understanding of epigenetic dysregulation in pancreatic cancer and how it is contributing to our efforts in early diagnosis, predictive and prognostic biomarker development and new therapeutic approaches in this deadly cancer.
No takes yet. Share an insight, caveat, or question.
Thompson et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: